Page last updated: 2024-09-03

y 27632 and tg 003

y 27632 has been researched along with tg 003 in 2 studies

Compound Research Comparison

Studies (y 27632)	Trials (y 27632)	Recent Studies (post-2010) (y 27632)	Studies (tg 003)	Trials (tg 003)	Recent Studies (post-2010) (tg 003)
1,924	3	891	45	0	33

Protein Interaction Comparison

Protein	Taxonomy	tg 003 (IC50)
Dual specificity protein kinase CLK2	Mus musculus (house mouse)	0.2
Dual specificity protein kinase CLK4	Mus musculus (house mouse)	0.015
Dual specificity protein kinase CLK1	Mus musculus (house mouse)	0.02
Dual specificity protein kinase CLK1	Homo sapiens (human)	0.064
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)	0.6172
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Mus musculus (house mouse)	0.012

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M	1
Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A	1

Other Studies

2 other study(ies) available for y 27632 and tg 003

Article	Year
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51 Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases	2007
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. The Biochemical journal, 2013, Apr-15, Volume: 451, Issue:2 Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase	2013

Article

Year

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007

A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

The Biochemical journal, 2013, Apr-15, Volume: 451, Issue:2

Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase

2013